Apply Now!
Interested in experimental treatment options not yet available to the public?
Click here to become a participant.
Interested in experimental treatment options not yet available to the public?
Click here to become a participant.
This study is for patients diagnosed with Chronic Idiopathic Constipation.
The purpose of the study is to assess effects of lower dose (72 ug) versus current approved dose (145 ug).
Participants will receive study medication and study visit services at no cost. Compensation for time and travel available.
Parallel-group Trial of Linaclotide (72 ug or 145 ug) Administered Orally for 12 Weeks to Patients with Chronic Idiopathic Constipation